Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C

Cancer Research

Volumn 64, Issue 11, 2004, Pages 3940-3948

  Wu, H Irene ^a   Brown, James A ^a   Dorie, Mary J ^a   Lazzeroni, Laura ^a   Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOMYCIN C; OXALIPLATIN; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DIPLOIDY; DNA CROSS LINKING; DNA REPAIR; DRUG SENSITIVITY; EXCISION REPAIR; GENE; GENE DELETION; GENE IDENTIFICATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PSO2 GENE; PSY1 GENE; PSY2 GENE; PSY3 GENE; SACCHAROMYCES CEREVISIAE; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA REPAIR; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE DELETION; GENOME, FUNGAL; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; SACCHAROMYCES CEREVISIAE;

EID: 2542541217     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3113     Document Type: Article

References (58)

1. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Investig. 1994;94:703-8.
2. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
3. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-16.
4. Park CH, Bessho T, Matsunaga T, Sancar A. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem 1995;270:22657-60.
5. Sijbers AM, de Laat WL, Ariza RR, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 1996;86:811-22.
6. Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M, Essigmann IM, Wood RD. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 2000;275:26632-6.
7. States JC, Reed E. Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Lett 1996;108:233-7.
8. Koberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999;9:273-6.
9. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903.
10. Takata M, Sasaki MS, Tachiiri S, et al. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 2001;21:2858-66.
11. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 2003;9:568-74.
12. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-90.
13. Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997;15:45-52.
14. Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997;57:1841-5.
15. Vaisman A, Chaney SG. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta. J Biol Chem 2000;275:13017-25.
16. Taylor EM, Lehmann AR. Conservation of eukaryotic DNA repair mechanisms. Int J Radiat Biol 1998;74:277-86.
17. Eisen JA, Hanawalt PC. A phylogenomic study of DNA repair genes, proteins, and processes. Mutat Res 1999;435:171-213.
18. Wang Z, Wu X, Friedberg EC. Nucleotide-excision repair of DNA in cell-free extracts of the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1993;90:4907-11.
19. Abe H, Wada M, Kohno K, Kuwano M. Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants. Anticancer Res 1994;14:1807-10.
20. Simon JA, Szankasi P, Nguyen DK, et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 2000;60:328-33.
21. Durant ST, Morris MM, Illand M, et al. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol 1999;9:51-4.
22. Grossmann KF, Ward AM, Matkovic ME, Folias AE, Moses RE. S. cerevisiae has three pathways for DNA interstrand crosslink repair. Mutat Res 2001;487:73-83.
23. Bruhn SL, Pil PM, Essigmann JM, Housman DE, Lippard SJ. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci USA 1992;89:2307-11.
24. Pil PM, Chow CS, Lippard SJ. High-mobility-group I protein mediates DNA bending as determined by ring closures. Proc Natl Acad Sci USA 1993;90:9465-9.
25. Brown SJ, Kellett PJ, Lippard SJ. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science (Wash DC) 1993;261:603-5.
26. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994;91:10394-8.
27. Furuchi T, Ishikawa H, Miura N, et al. Two nuclear proteins, Cin5 and Ydr259c, confer resistance to cisplatin in Saccharomyces cerevisiae. Mol Pharmacol 2001;59:470-4.
28. Schenk PW, Boersma AW, Brandsma JA, et al. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer Res 2001;61:6982-6.
29. Giaever G, Chu AM, Ni L, Connelly C, et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature (Lond) 2002;418:387-91.
30. Birrell GW, Giaever G, Chu AM, Davis RW, Brown JM. A genome-wide screen in Saccharomyces cerevisiae for genes affecting UV radiation sensitivity. Proc Natl Acad Sci USA 2001;98:12608-13.
31. Bennett CB, Lewis LK, Karthikeyan G, et al. Genes required for ionizing radiation resistance in yeast. Nat Genet 2001;29:426-34.
32. Game JC, Birrell GW, Brown JA, et al. Use of a genome-wide approach to identify new genes that control resistance to Saccharomyces cerevisiae to ionizing radiation. Radiat Res 2003;160:14-24.
33. Chang M, Bellaoui M, Boone C, Brown GW. A genome-wide screen for methyl methanesulfonate-sensitive mutants reveals genes required for S phase progression in the presence of DNA damage. Proc Natl Acad Sci USA 2002;99:16934-9.
34. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001;48:398-406.
35. Winzeler EA, Shoemaker DD, Astromoff A, et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science (Wash DC) 1999;285:901-6.
36. Birrell GW, Brown JA, Wu HI, et al. Transcriptional response of Saccharomyces cerevisiae to DNA-damaging agents does not identify the genes that protect against these agents. Proc Natl Acad Sci USA 2002;99:8778-83.
37. Nelson JR, Lawrence CW, Hinkle DC. Thymine-thymine dimer bypass by yeast DNA polymerase zeta. Science (Wash DC) 1996;272:1646-9.
38. Game JC. New genome-wide methods bring more power to yeast as a model organism. Trends Pharmacol Sci 2002;23:445-7.
39. Schaus SE, Cavalieri D, Myers AG. Gene transcription analysis of Saccharomyces cerevisiae exposed to neocarzinostatin protein-chromophore complex reveals evidence of DNA damage, a potential mechanism of resistance, and consequences of prolonged exposure. Proc Natl Acad Sci USA 2001;98:11075-80.
40. Eckardt-Schupp F, Klaus C. Radiation inducible DNA repair processes in eukaryotes. Biochimie 1999;81:161-71.
41. Begley TJ, Rosenbach AS, Ideker T, Samson LD. Damage recovery pathways in Saccharomyces cerevisiae revealed by genomic phenotyping and interactome mapping. Mol Cancer Res 2002;1:103-12.
42. van Gool AJ, Verhage R, Swagemakers SM, et al. RAD26, the functional S. cerevisiae homolog of the Cockayne syndrome B gene ERCC6. EMBO J 1994;13:5361-9.
43. Bhatia PK, Verhage RA, Brouwer J, Friedberg EC. Molecular cloning and characterization of Saccharomyces cerevisiae RAD28, the yeast homolog of the human Cockayne syndrome A (CSA) gene. J Bacteriol 1996;178:5977-88.
44. Dronkert ML, Kanaar R. Repair of DNA interstrand cross-links. Mutat Res 2001;486:217-47.
45. Dronkert ML, de Wit J, Boeve M, et al. Disruption of mouse SNM1 causes increased sensitivity to the DNA interstrand cross-linking agent mitomycin C. Mol Cell Biol 2000;20:4553-61.
46. Masson JY, Ramotar D. The Saccharomyces cerevisiae IMP2 gene encodes a transcriptional activator that mediates protection against DNA damage caused by bleomycin and other oxidants. Mol Cell Biol 1996;16:2091-100.
47. Leonetti C, Biroccio A, Gabellini C, et al. Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 2003;104:243-50.
48. Yen HC, Nien CY, Majima HJ, et al. Increase of lipid peroxidation by cisplatin in W138 cells but not in SV40-transformed WI38 cells. J Biochem Mol Toxicol 2003;17:39-46.
49. Herman M, Ori Y, Chagnac A, et al. DNA repair in mononuclear cells: role of serine/threonine phosphatases. J Lab Clin Med 2002;140:255-62.
50. Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989;43:237-50.
51. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993;53:5970-6.
52. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998;54:770-7.
53. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994;54:3500-5.
54. Vaisman A, Masutani C, Hanaoka F, Chaney SG. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 2000;39:4575-80.
55. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
56. Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998;58:3579-85.
57. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43.
58. Prakash S, Prakash L. Nucleotide excision repair in yeast. Mutat Res 2000;451:13-24.